-

TriMas Life Sciences Expands Its Cleanroom Capabilities

Positions Company for Growth in Medical Technology Applications

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--TriMas (NASDAQ: TRS) today announced that its Intertech business, part of the TriMas Life Sciences division, has expanded its cleanroom capacity at its Denver, Colorado, facility. The additional production space addresses increased customer demand for highly engineered components used in medical technology applications, such as for use in testing, vascular delivery and extraction applications.

Intertech recently expanded its ISO Class 8 cleanroom molding and assembly capacity by an additional 3,400 square feet, including dedicated space for molding presses and secondary operation equipment. The addition complements Intertech’s existing 9,000-plus square feet of ISO Class 8 cleanroom capacity. In addition, TriMas has invested in additional cleanroom capabilities at a second facility in the Denver area, under Intertech’s existing ISO 13485 Medical Devices Quality Management Systems certification.

“Our increased investments in the Life Sciences end market continue to be an important long-term strategic enhancement for TriMas,” commented Thomas Amato, TriMas President and Chief Executive Officer. “By expanding our cleanroom production capabilities, we are addressing the growing demand needs of our customers, while remaining at the forefront of stringent regulatory standards. This investment not only underscores our dedication to operational excellence and superior quality, but also reaffirms our commitment to serving the evolving needs of the Life Sciences sector.”

In addition to its certified ISO Class 8 cleanroom environments, Intertech’s manufacturing facility, located in Denver, Colorado, is also MedAccred® accredited.

The TriMas Life Sciences division, which is comprised of the Intertech and Omega businesses, as well as certain pharmaceutical and nutraceutical product lines, manufactures complex, precision injection molded components and assemblies for applications in the Life Sciences end market. TriMas Life Sciences’ capabilities and products include rapid prototype capability, as well as production molds, and custom, medical-related components such as consumable vascular delivery, patient monitoring and diagnostic test components, surgical devices, pharmaceutical airless dispensers and nutraceutical closures. TriMas Life Sciences collaborates with clients to deliver safe, compliant and “part perfect” products and components that positively impact people’s lives. For more information, please visit www.trimaslifesciences.com.

About TriMas

TriMas manufactures a diverse set of products primarily for the consumer products, aerospace and industrial markets through its TriMas Packaging, TriMas Aerospace and Specialty Products groups. Our approximately 3,500 dedicated employees in 13 countries provide customers with a wide range of innovative and quality product solutions through our market-leading businesses. Our TriMas family of businesses has strong brand names in the markets served, and operates under a common set of values and strategic priorities under the TriMas Business Model. TriMas is publicly traded on the NASDAQ under the ticker symbol “TRS,” and is headquartered in Bloomfield Hills, Michigan. For more information, please visit www.trimas.com.

Contacts

Sherry Lauderback
VP, Investor Relations & Communications
(248) 631-5506
sherry.lauderback@trimas.com

TriMas

NASDAQ:TRS

Release Versions

Contacts

Sherry Lauderback
VP, Investor Relations & Communications
(248) 631-5506
sherry.lauderback@trimas.com

More News From TriMas

TriMas Announces New Chief Financial Officer

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--TriMas (NASDAQ: TRS) today announced the appointment of Paul Swart as Chief Financial Officer, effective December 15, 2025. Paul will report to Thomas Snyder, TriMas President and Chief Executive Officer, and will succeed Teresa Finley, Interim Chief Financial Officer and TriMas Board Member. Paul brings more than 25 years of strategic leadership and financial oversight experience, including two decades in key operational and corporate finance and accou...

TriMas Announces Increased Share Repurchase Authorization to $150 Million

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--TriMas (NASDAQ: TRS) today announced that its Board of Directors has increased the Company’s common stock share repurchase authorization to a total of up to $150 million, adding to the $65.4 million remaining under the previous authorization. “Increasing our share repurchase authorization reinforces our long-term commitment to returning capital to shareholders and the Board’s confidence in TriMas’ future,” said Thomas Snyder, TriMas President and Chief...

TriMas Enters Into Agreement to Sell TriMas Aerospace for $1.45 Billion

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--TriMas (NASDAQ: TRS) announced today that it has entered into a definitive agreement to sell its Aerospace segment for an all-cash purchase price of approximately $1.45 billion to an affiliate of Tinicum L.P. (the “Transaction”). Funds managed by Blackstone will be a minority investor in the Transaction. The purchase price represents an enterprise value multiple of approximately 18x last twelve months (LTM) third quarter 2025 adjusted EBITDA(1). “As pre...
Back to Newsroom